首页> 外文期刊>Heart disease: A journal of cardiovascular medicine >Colesevelam: a new bile acid sequestrant.
【24h】

Colesevelam: a new bile acid sequestrant.

机译:Colesevelam:一种新的胆汁酸螯合剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Coronary heart disease is the most prevalent form of cardiovascular disease in the United States. Hyperlipidemia--specifically, increased total and low-density lipoprotein cholesterol levels--positively correlates with the development of coronary heart disease. Colesevelam, a nonabsorbed, water-insoluble polymer, is a new bile acid sequestrant that is effective in lowering total and low-density lipoprotein cholesterol levels. In several short-term, placebo-controlled studies, colesevelam has decreased total cholesterol levels by approximately 6 to 10% and low-density lipoprotein cholesterol levels by approximately 9 to 20%. When given in combination with atorvastatin, lovastatin, or simvastatin, low-density lipoprotein cholesterol levels were decreased more than with colesevelam alone. Its unique hydrogel formulation may also minimize the potential for gastrointestinal adverse effects, which are common with other bile acid sequestrants. There have been few published studies available concerning this drug; no long-term studies and few large-scale studies have been published.
机译:冠心病是美国最常见的心血管疾病。高脂血症-特别是总和低密度脂蛋白胆固醇水平升高-与冠心病的发展呈正相关。 Colesevelam是一种不吸收水的不溶性聚合物,是一种新型的胆汁酸螯合剂,可有效降低总密度和低密度脂蛋白胆固醇水平。在一些短期,安慰剂对照的研究中,西洛仑仑将总胆固醇水平降低了约6至10%,而低密度脂蛋白胆固醇水平降低了约9至20%。当与阿托伐他汀,洛伐他汀或辛伐他汀联合使用时,低密度脂蛋白胆固醇水平的下降幅度要比单独使用西洛韦仑的下降幅度更大。其独特的水凝胶配方还可以最大程度地降低胃肠道不良反应的可能性,这是其他胆汁酸螯合剂常见的情况。关于这种药物的公开研究很少。没有长期研究,也没有发表大规模研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号